CompletedPhase 2

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease

Lead sponsor

T3D Therapeutics, Inc.

Asset

T3D-959

Listed sites

Recruiting sites

Enrollment

250

actual

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•CDR-SB ≥3•MMSE 14-26•Study partner/caregiver required

Primary endpoints

•ADAS-Cog•Efficacy of T3D-959 on function•Safety and tolerability of T3D-959

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih1R01AG061122

NCT IDNCT04251182

Org study IDT3D959-202

Timeline

Milestones

Study first posted2020-01-31actual

Study start2021-03-01actual

Primary completion2023-01-20actual

Study completion2023-02-17actual

Last update posted2024-07-19actual

Assets

Drug assets

T3D-959

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have a reliable caregiver, an identified adult who, in the opinion of the investigator has sufficient contact to knowledgeably report on the subject's daily cognition, function, behavior, safety, compliance and adherence. Same caregiver(s) must assist the subject throughout the duration of the trial.

•Have a clinical diagnosis of mild-to-moderate AD (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening

•Meet criteria for mild-to-moderate cognitive impairment with Mini-Mental State Examination (MMSE) score of 14 through 26 at the screening visit.

•Neuroimaging evidence consistent with the diagnosis of AD

•Modified Hachinski </= 4 at screening

•Clinical Dementia Rating is 0.5 to 2.0 at screening and Clinical Dementia Rating - Sum of Boxes is ≥ 3 at screening

•Visual and auditory acuity adequate for neuropsychological testing

•No evidence of hepatic impairment or renal insufficiency

Exclusion criteria

•Have a current diagnosis of a significant psychiatric illness per the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V)

•With untreated clinical depression (GDS >/= 6 at screening and baseline)

•Have a current diagnosis of a neurological disease other than AD

•With glycosylated hemoglobin (HbA1c) >/= 7.7 at screening

•With a diagnosis of unstable diabetes

•With clinically significant thyroid disease at screening TSH >5

•Have any of the following values at the screening visit:

-ALT and/or AST value that is twice the upper limit of normal

-Total bilirubin value that exceeds 2 mg/dL

-Creatinine level >1.5 mg/dL in men or > 1.4 mg/dL in women

-Positive urinalysis (other than trace result) unless a cause other than renal impairment

-Glomerular filtration rate (GFR) values <54 mL/min/1.73 m2

-Gamma-glutamyl transpeptidase (GGT) value that is twice the upper limit of normal

-Is positive for hepatitis B or anti-hepatitis C virus antibodies at the screening

•Have a history of moderate or severe congestive heart failure, NYHA class III or IV

•Have experienced a previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 12 months prior to the baseline

•Have blood pressure reading at screening that is greater than 160/100 mmHg

•Have a clinically significant unstable illness

•Have a history of HIV infection

•Have a history of alcohol, drug abuse or dependence

•Have a history of cancer within 5 years of the screening

•Have any surgical or medical condition which may significantly alter the absorption of any drug substance

•Females who are pregnant, nursing or of childbearing potential and not practicing effective contraception

•Is required to take excluded medications as specified protocol

•Have a known or suspected intolerance or hypersensitivity to the study drug, closely related compounds

•Resides in hospital or moderate to high dependency continuous care facility

•Are non-ambulatory, or wheelchair-bound

•Have evidence of clinically relevant pathology that in the investigator's opinion could interfere with the study results or put the subject's safety at risk

•History of swallowing difficulties

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Executive function / language

Behavior / neuropsychiatric

Fluid / digital biomarkers

Other clinical outcomes

Other (unclassified)